[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640340":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":121,"collaborators":123,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":128,"sex":134,"minAge":10,"maxAge":10,"enrollmentInfo":135,"targetDuration":10,"studyType":138,"phases":10,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":146,"whyStopped":10,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Denys-Drash syndrome",null,"Patients who were minors at the time of kidney transplantation between 2000 and 2022.",[13],"Other: Collection of data from the patient's medical file",{"label":15,"type":10,"description":16,"interventionNames":17},"Control patients","The controls will be matched in chronological order of transplantation with patients with Denys-Drash syndrome: a control before and a control after, matched according to the Epstein-Barr virus status of the pretransplant recipient, the Epstein-Barr virus status of the donor and the age of transplantation.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Collection of data from the patient's medical file","Collection of data from the patient's medical file. The data will be collected until 2024.",[15,9],[24],{"name":25,"affiliation":5,"role":26},"Mathilde M.D. Grapin","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","0033142192726","mathilde.grapin@aphp.fr",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Hélène Morel","33171196346","helene.morel@aphp.fr",[37,56,69,78,87,100,111],{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hôpital Femme Mère Enfant, Hospices Civils de Lyon","Bron","69500","France","FR",{"type":44,"coordinates":45},"Point",[46,47],4.91303,45.73865,{"lat":47,"lon":46},[50,53],{"name":51,"role":29,"phone":10,"phoneExt":10,"email":52},"Justine MD, PhD Bacchetta","justine.bacchetta@univ-lyon1.fr",{"name":54,"role":29,"phone":10,"phoneExt":10,"email":55},"Anne-Laure M.D. Sellier","anne-laure.sellier-leclerc@chu-lyon.fr",{"facility":57,"status":10,"city":58,"state":10,"zip":59,"country":41,"countryCode":42,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"CHU de Lille","Lille","59000",{"type":44,"coordinates":61},[62,63],3.05512,50.63391,{"lat":63,"lon":62},[66],{"name":67,"role":29,"phone":10,"phoneExt":10,"email":68},"Robert M.D. Novo","robert.novo@chu-lille.fr",{"facility":70,"status":10,"city":71,"state":10,"zip":72,"country":41,"countryCode":42,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"CHU Montpellier","Montpellier","34000",{"type":44,"coordinates":74},[75,76],3.87635,43.61093,{"lat":76,"lon":75},{"facility":79,"status":10,"city":80,"state":10,"zip":81,"country":41,"countryCode":42,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"CHU de Nancy - Hôpitaux de Brabois","Nancy","54500",{"type":44,"coordinates":83},[84,85],6.18496,48.68439,{"lat":85,"lon":84},{"facility":88,"status":10,"city":89,"state":10,"zip":90,"country":41,"countryCode":42,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Hôpital enfants et adolescents, CHU Nantes","Nantes","44093",{"type":44,"coordinates":92},[93,94],-1.55336,47.21725,{"lat":94,"lon":93},[97],{"name":98,"role":29,"phone":10,"phoneExt":10,"email":99},"Gwenaelle M.D. Roussey","gwenaelle.roussey@chu-nantes.fr",{"facility":101,"status":10,"city":102,"state":10,"zip":103,"country":41,"countryCode":42,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Hôpital Necker-Enfants Malades","Paris","75015",{"type":44,"coordinates":105},[106,107],2.3488,48.85341,{"lat":107,"lon":106},[110],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},{"facility":112,"status":10,"city":102,"state":10,"zip":113,"country":41,"countryCode":42,"cosmosGeoPoint":114,"geoPoint":116,"contacts":117},"Hôpital Robert Debré","75019",{"type":44,"coordinates":115},[106,107],{"lat":107,"lon":106},[118],{"name":119,"role":29,"phone":10,"phoneExt":10,"email":120},"Julien MD, PhD Hogan","julien.hogan@aphp.fr",{"type":122,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[124],{"name":125,"class":6},"URC-CIC Paris Descartes Necker Cochin","100640340","denys-drash-syndrome-and-risk-of-post-transplant-lymphoproliferative-disorder-100640340",false,"NCT07605884","Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder","Post-transplant Lymphoproliferative Disorder Following Kidney Transplantation in Denys-Drash Syndrome: a Case-control Study","DRASH-PTLD","Inclusion Criteria:\n\n* Patient must be a minor at the time of kidney transplantation\n* Diagnosis of Denys-Drash syndrome (WT1 pathogenic variants in exons 8 or 9) for cases\n* Controls: minor patient, kidney transplanted at the same center as the case, immediately before and immediately after the case\n* Kidney transplant recipient on immunosuppressants\n* Hospital follow-up in a participating center in France\n* Regardless of their Epstein-Barr virus status before transplantation\n* Between 2000 and 2022\n* Holders of parental authority or adult patients informed of the study and not objecting to the processing of medical data for the study\n\nExclusion Criteria:\n\n* History of lymphoproliferative disorder prior to transplantation\n* Other hematopoietic cancer\n* Other genetic disease with a proven increased risk of lymphoproliferative disorder","ALL",{"count":136,"type":137},108,"ESTIMATED","OBSERVATIONAL","Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).\n\nThe aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.",[141],"Denys-Drash Syndrome",[143,144,145],"Denys-Drash syndrome","Post-transplant lymphoproliferative disorder","Kidney transplantation","NOT_YET_RECRUITING","2026-05-18",{"date":149,"type":150},"2026-05-26","ACTUAL",{"date":152,"type":137},"2026-06",{"date":154,"type":137},"2027-06",{"name":5,"class":6},7]